B2BROKER
25.1.2022 13:02:11 CET | Business Wire | Press release
B2Broker , a leading liquidity and technology provider of solutions to the Forex and financial services industry, has secured a licence from the Financial Services Commission (FSC) Mauritius , the company has announced. The licence has been acquired under the name of B2B Prime Services Limited, a member of the B2Broker Group of Companies, which as of 12th November, 2021, possesses an Investment Dealer licence (Full Service Dealer excluding underwriting /code SEC-2.1, Licence # C117017139).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005241/en/
Description of Authorised Activity
As an authorised Dealer in Securities, B2B Prime Services is permitted to act as intermediary in the execution of securities transactions for clients in accordance with the country’s local legislation. Under Mauritius regulation, the company will operate as a Prime of Prime (PoP) Multi-Asset Liquidity Provider, focusing on institutional and professional clients across the whole spectrum of the financial markets. Its core investment services consist of leveraged derivative products in CFDs (e.g. Forex, metals, commodities, shares, indices).
About the FSC
The FSC is the integrated regulator in Mauritius for the financial services sector and was established in 2001 to licence, regulate, monitor and supervise the conduct of business activities in these sectors in accordance with local legislation. The regulator is committed to the sustained development of Mauritius as a sound and competitive Financial Services Centre with the aim of promoting the development, fairness, efficiency and transparency of financial institutions and capital markets, suppressing crime and malpractices so as to provide protection to members of the public investing in non-banking financial products, and ensuring the soundness and stability of the financial system in Mauritius.
About B2Broker Group of Companies
B2Broker is a global brand with a solid reputation in the B2B sphere as one of the most in-demand technology and liquidity providers for Forex and crypto brokers, crypto exchanges and other financial services entities. The group helps these firms empower their businesses through building a successful, transparent and ethical environment and connecting them to the markets in a short space of time and at a reasonable cost.
B2Broker offers a broad range of services including Crypto/Forex/CFD liquidity, Crypto/Forex Broker turnkey solutions, crypto payment processing (B2BinPay), MT4/5 white label solutions, B2Core (Trader’s Room) , B2Trader (Matching Engine) and liquidity on over 800 trading instruments across the entire spectrum of assets.
Headquartered in Moscow, B2Broker has several years of operational experience with 10 offices in 8 countries across Russia, Europe, Asia and MENA. A total of 7 licences so far to its name including FCA, AEMI, Central Bank of Russia, and now FSC, allows B2Broker to serve clients across more than 50 countries, offering Forex liquidity distribution and a range of other services to the Forex, Crypto and Securities industries. The company has secured a large portfolio of well-known global clients in the financial services industry with plans to further increase company representation and visibility across the globe.
CEO and Founder of B2Broker Group, Arthur Azizov, commented, “We are pleased to have added another prestigious licence to our growing portfolio. The licence ensures the reliability and transparency of all operations in accordance with the strict supervision of the FSC and adds further credibility to us as a leading global fintech player. Industry regulation is undoubtedly the best way to achieve total legitimisation of the Forex and financial services industry and our latest licence acquisition means that even more clients across the world will be able to benefit from the highest level of protection offered by one of the world’s leading, multi-regulated technology and liquidity providers.”
The acquisition of the latest FSC licence broadens B2Broker’s horizons enabling the company to secure further business in its quest to expand its global reach. Aside from this latest licence acquisition, the company currently has several other licence applications with established regulators in process which are expected to be concluded during 2022.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220125005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom